Phase III OASIS-2 study of mirikizumab meets all primary endpoints vs secukinumab in plaque psoriasis

Mirikizumab, an investigational monoclonal antibody that binds to the p19-subunit of IL23, achieved PASI 90 at week 16 and at least a 2-point improvement in Physician's Global Assessment vs placebo and superiority vs secukinumab.


Biospace Inc.